Are there any upcoming catalyst events (e.g., data readouts, FDA meetings, conference presentations) that could move the stock price?

Catalyst Outlook

The press release only covers the Q2‑2025 earnings and “recent developments” but does not name a specific upcoming data read‑out, FDA meeting, or conference slot. However, given Monopar’s clinical‑stage status, the most likely near‑term catalysts are:

Trading implications

• Short‑term: Until a concrete data‑release or FDA meeting is announced, the stock will likely trade on the “earnings‑plus‑development” narrative. Expect modest volatility around the Q2 results, with the price holding near the post‑earnings support level (≈ $0.85‑$0.90) and facing resistance around the recent high (≈ $1.10).
  
• Medium‑term: The true driver will be the first major data read‑out. If the company signals a Q3‑Q4 data release in an upcoming investor call or a conference abstract, the market will price in a “catalyst premium” and the stock could rally 15‑30 % on a clean read‑out. Conversely, a delayed or negative read‑out will expose the stock to a downside break of the Q2 support zone.
  
• Actionable stance: Maintain a watch‑list position now. If the company files a 8‑K or issues a press‑release confirming a specific data‑readout date or an FDA meeting, consider a long‑bias entry on a breakout above $1.10 with a stop just below $0.85. In the absence of a confirmed catalyst, a tight range‑bound approach (buy on dips near $0.88, sell on rallies near $1.05) is prudent.
  

Bottom line: No explicit catalyst is disclosed in the Q2 release, but the company’s pipeline milestones—particularly a Phase 2/3 data read‑out, an FDA meeting, or a conference presentation—are the key events that could move MNPR’s price in the coming months. Keep a close eye on any forthcoming 8‑K filings or conference abstracts that lock in those dates.